| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Recent developments indicate a strong interest in a sector characterized by robust acquisitions and partnerships, particularly evident through significant deals such as Amgen's acquisition of Dark Blue Therapeutics. The focus on AI-driven drug discovery suggests a transformative approach within major companies, while oncology and drug sales remain at the forefront of discussions, signaling growth potential. However, the competitive landscape exacerbated by Big Pharma's patent cliffs introduces challenges that could stifle innovation. Despite these hurdles, the sector is indicated to be on a recovery path, fueled by market positivity around sales expectations and product advancements. The price action of Biotechnology (IBB) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The trend sentiment at 0.1 is modestly bullish. The market sentiment at 0.5 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.IBB is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for Biotechnology sector is at 0.5, and the negative at 0 on 2026-01-13. The forces of Sentiment towards Fundamentals (1.6), Market Risk Appetite (0.9), Broad Market Trend (0.3), Option Sentiment (0.1), Sector Price Trend (0.1), Price Level Sentiment (0), and Valuation Sentiment (0) will drive up the price. The forces of and Valuation Sentiment (0) will drive down the price. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on IBB trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| IBB | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-13 | 1%(0.3%) | 171.32 | 57 | -0.05% | 0% | 0.1 | -0.06% | 0.6% | 0.5 | Wait | 50% | 1.6 | 6.3 |
| 2026-01-12 | 1%(0.3%) | 171.4 | 59 | -0.57% | 0% | 0.7 | -0.06% | 0.9% | 0.5 | Long | 65% | 2 | 5.5 |
| 2026-01-11 | 0%(0.1%) | 0.5 | -0.06% | 0.5 | 1.5 | -0.5 | |||||||
| 2026-01-10 | 0%(0.3%) | 0.5 | -0.06% | 0.4 | 1.1 | -0.5 | |||||||
| 2026-01-09 | 0%(0.3%) | 172.39 | 71 | 0.08% | -0.06% | 0.5 | -0.06% | 0.9% | 0.4 | Long | 65% | 1.1 | 1.3 |
| 2026-01-08 | 0%(0.3%) | 172.26 | 70 | -2.53% | 0% | 0.6 | 0.06% | 1.2% | 0.4 | Wait | 50% | 1.6 | 2.2 |
| 2026-01-07 | 0%(0.3%) | 176.74 | 119 | 3.21% | 0.23% | 0.9 | 0.29% | 1.9% | 0.5 | Short | 88% | 2.5 | 5.5 |
| 2026-01-06 | 1%(0.4%) | 171.24 | 70 | 2.3% | 0.06% | 0.2 | 0.06% | 1.1% | 0.7 | Long | 60% | 2 | 6.7 |
| 2026-01-05 | 0%(0.3%) | 167.39 | 20 | -0.95% | 0.06% | -0.3 | -0.06% | 0.8% | 0.6 | Wait | 50% | 1.7 | 7.5 |
| 2026-01-04 | 1%(0.3%) | -0.3 | -0.08% | 0.3 | 1.2 | 7.5 | |||||||
| Wait is the preferred trading strategy with 50% chance of being right. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| Analysis | ||
| ● Rules, Risk & Reward: How Regulation Is Shaping Biotech (IBB) Sun. Oct 5, 2025 | ||
| ● A Summary of Recent Product/Service Development in Biotech Sector Sun. Oct 5, 2025 | ||
| ● Biotech Earnings Check-In: Where Strength Is Building (and Where It Isn’t) Sun. Oct 5, 2025 | ||
| Market News | ||
| 1 (6) Novo’s CEO Ready to Go ‘Very Big’ in Hunt for Obesity Deals Novo Nordisk A/S is back on the hunt for deals to boost its obesity portfolio after losing US biotech Metsera Inc. in a bidding war with Pfizer Inc. late last year. (https://www.bloomberg.com/) Tue. Jan 13, 2026 | ||
| 2 (4) Amgen CEO says weight loss drug can address 'patient persistence issue' Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer. (https://www.cnbc.com/) Tue. Jan 13, 2026 | ||
| 3 (8) Illumina Preliminary Q4, Annual Results Beat Analysts' View Illumina, Inc. (ILMN), a biotechnology company, on Tuesday reported preliminary results for the fourth quarter and fiscal 2025 above analysts' expectations. For the fourth quarter of 2025, the company expects net profit of $2. (https://www.rttnews.com/) Tue. Jan 13, 2026 | ||
| 4 (6) AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs. AbbVie stock was rising. The drugmaker has agreed to cut some prices in exchange for an exemption from some Trump Tariffs. (https://www.barrons.com/) Tue. Jan 13, 2026 | ||
| 5 (7) Bristol Says New Version of Opdivo on Track to Meet Target Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at least 30% of patients in two years. (https://www.bloomberg.com/) Tue. Jan 13, 2026 | ||
| 6 (7) Why Moderna Stock Strength Is Only Beginning: Technical Analysis Moderna stock is now putting its foot on the accelerator in 2026—and the chart suggests that more gains are coming. (https://www.barrons.com/) Tue. Jan 13, 2026 | ||
| 7 (8) Why Moderna Stock Strength Is Only Beginning: Technical Analysis Moderna stock is now putting its foot on the accelerator in 2026—and the chart suggests that more gains are coming. (https://www.barrons.com/) Tue. Jan 13, 2026 | ||
| 8 (8) Amgen Growth Story Isn't Tapped Out Yet, Says Goldman Goldman Sachs reiterates Buy rating and $403 price target for Amgen due to strong portfolio execution and 6 key growth drivers. (https://www.benzinga.com/) Tue. Jan 13, 2026 | ||
| 9 (8) A Compelling 'Picks and Shovels' Play on the Future of Gene Therapy This stock offers truly asymmetrical risk and a margin of safety that most biotech stocks lack. Here's what investors should know. (https://www.thestreet.com/) Mon. Jan 12, 2026 | ||
| 10 (-5) Why Moderna Stock Is Dropping After Good News Moderna’s 2028 cash breakeven guidance may not be feasible, analysts say. (https://www.barrons.com/) Mon. Jan 12, 2026 | ||
| 11 (8) Nvidia, Eli Lilly announce $1 billion investment in AI drug discovery lab Nvidia and Eli Lilly are set to launch an AI lab in San Francisco. (https://finance.yahoo.com/) Mon. Jan 12, 2026 | ||
| 12 (8) This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. Lilly is prepared to offer around $17.5 billion to acquire Abivax, a local media report suggests. (https://www.barrons.com/) Mon. Jan 12, 2026 | ||
| 13 (8) Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab SAN FRANCISCO, Jan 12 () - Nvidia and U. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area over five years which will use Nvidia's newest generation Vera Rubin AI chips, the firms said on Monday. (https://finance.yahoo.com/) Mon. Jan 12, 2026 | ||
| 14 (8) AbbVie, RemeGen partner on experimental solid tumor treatment Jan 12 () - AbbVie said on Monday it would partner with RemeGen to develop an experimental treatment for solid tumors in a deal worth up to $4.95 billion, including milestones. (https://finance.yahoo.com/) Mon. Jan 12, 2026 | ||
| 15 (7) Moderna expects $1.9 billion in sales, trims costs forecast for 2025 Jan 12 (Reuters) - Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its previously projected $1. (https://finance.yahoo.com/) Mon. Jan 12, 2026 | ||
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA